The BCTRIMS expanded consensus on treatment of multiple sclerosis. I. The evidences for the use of immunossupressive agents, plasma exchange and autologous hematopoietic stem cell transplantation;Consenso expandido do BCTRIMS para o tratamento da esclerose múltipla. I. As evidências para o uso de imunossupressores, plasmaférese e transplante autólogo de células tronco

Arquivos de Neuro-Psiquiatria

Volumn 60, Issue 3 B, 2002, Pages 869-874

  Callegaro, Dagoberto ^a   Lana Peixoto, Marco Aurélio ^a   Moreira, Marcos Aurélio ^a   Marchiori, Paulo Eurípedes ^a   Bacheschi, Luiz Alberto ^a   Arruda, Walter Oleschko ^a   Campos, Gilberto Belisário ^a   Martins Lino, Angelina Maria ^a   Souza Melo, Aílton ^a   Gomes da Rocha, Fernando Coronetti ^a   Brito Ferreira, Maria Lúcia ^a   Ataíde Jr , Luiz ^a   Kaiman Maciel, Damacio Ramón ^a   Gabbai, Alberto Alain ^a   Teixeira Jr , Antônio Lúcio ^a   Da Fonseca Filho, Ayrton Gomes ^a   Santos de Oliveira, Bianca Etelvina ^a   Stella, Carla Vieira ^a   De Almeida Boer, Carlos Alberto ^a   Silveira Pagliuso, Carlos Antônio ^a   Brandão, Carlos Otávio ^a   Araújo, Carolina Reis ^a   Botelho, Caroline Miranda ^a   Pirani Jr , Clodoaldo ^a   Diniz, Denise Sisterolli ^a   Comini Frota, Elizabeth Regina ^a   Tosta da Silva, Elza Dias ^a   Bahadian Bardy, Fernanda ^a   Di Biase, Francisco ^a   Silva Malveira, George Linard ^a   Reis, Igor Levy ^a   Urbano da Silva, Jair ^a   Coral, Luiz Carlos ^a   Antônio da Silva, Márcio ^a   Peterlevitz, Marcos Aurélio ^a   Amaral Lorenti, Maria Ângela ^a   Mendes, Maria Fernanda ^a   Guimarães Rocha, Maria Sheila ^a   Da Cunha, Mauro Pedro ^a   Goulart, Norton Tadeu ^a   Discher Sá, Paulo Norberto ^a   Da Nóbrega, Paulo Virgolino ^a   Domingues, Renan Barros ^a   Buainain, Renata Parissi ^a   De Rizo Morales, Rogério ^a   Ferreira de Rezende, Rosana ^a   De Melo Souza, Sebastião Eurico ^a   Haussen, Sérgio Roberto ^a   Fenelon, Sheila Bernardino ^a   Lacerda, Shirley Silva ^a   Gomes, Sidney ^a   Nunes Machado, Suzana Costa ^a   De Oliveira Yokomizo, Tatiana ^a   Haase, Vitor Geraldi ^a   De Góes Horta, Wagner ^a   Teixeira, Walter Roque ^a   Fragoso, Yara Dadalti ^a   Ribeiro de Araújo, Yuna ^a   more..

^a NONE   (Brazil)

Author keywords

Autologous hematopoietic stem cell transplantation; Immunosuppressive agents; Multiple sclerosis; Plasma exchange; Treatment

Indexed keywords

AZATHIOPRINE; CLADRIBINE; CORTICOTROPIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MITOXANTRONE; PREDNISONE;

ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BRAZIL; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DRUG INDICATION; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MEDICAL SOCIETY; MULTIPLE SCLEROSIS; PLASMAPHERESIS; PRACTICE GUIDELINE; PUBLICATION; TREATMENT INDICATION;

EID: 0036736067     PISSN: 0004282X     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0004-282x2002000500035     Document Type: Article

References (38)

1. Oxman AD, Guyatt GH. Guidelines for reading literature reviews. Can Med Ass J 1988;138:697-703.
2. Cook DJ, Guyatt GH, Laupacis A and Sackett DL. Rules of evidence and clinical recommendation on the use of antithrombotic agents. Chest 1992;102(Suppl 4):3055-3115.
3. Report of the Quality Standards Subcommittee. Practice Advisory on Selection of Patients with Multiple Sclerosis for Treatment with Betaseron. Neurology 1994;44:1537-1540.
4. Goodin DS, Frohman EM, Garmany GPJr, et al. Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002;58:169-178.
5. Chabner BA, Allegra CJ, Curt GA, Calabresi P. Antineoplastic agents. In Hardman JG, Molinoff PB, Gilman AG. Goodman & Gilman's pharmacological basis of therapeutics. 9.Ed. New York: McGraw-Hill Companies, 1996:1233-1299.
6. Girard P, Aimard G, and Pellet H. Therapeutique immunodepressive en neurologie. Presse Med 1967;75:967-969.
7. Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosupression in progressive multiple sclerosis: a randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983;308:173-180.
8. Goodkin DE, Plencer S, Palmer SJ, Teetzen M, Hertsgaard D. Cyclophosphamide in chronic progressive multiple sclerosis. Arch Neurol 1987;44:823-827.
9. Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991;337:441-446.
10. Weiner HL, Mackin GA, Orav EJ, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 1993;43:910-918.
11. Silberberg D, Lizak R, Zweiman B. Multiple sclerosis unaffected by azathioprine in pilot study. Arch Neurol 1973;28:210-12.
12. Swinburn WR, Liversedge LA. Long-term treatment of multiple sclerosis with azathioprine. J Neurol Neurosurg Psychiatry 1973;36:124-26.
13. British and Dutch Multiple Sclerosis Azathioprine Trial Group. Double-masked trial of azathioprine in multiple sclerosis. Lancet 1988;2:179-83.
14. Ellison GW, Myers LW, Mickey MR, et al. A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis. Neurology 1989;39:1018-1026.
15. Cavazzutti M, Merelli E, Tassone G, Mavilla L. Lesion load quantification in serial MR of early relapsing multiple sclerosis pacients in azatioprine treatment. Eur Neurol 1997;38:284-290.
16. Confavreux C, Saddier P, Grimaud J, Moreau Th. Adeleine P, Aimard G. Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology 1996;46:1607-1612.
17. Neumann JW, Ziegler DK. Therapeutic trial of immunossupressive agents in multiple sclerosis. Neurology 1972;22:1268-1271.
18. Currier RD, Haerer AF, Meydrech EF. Low dose oral methotrexate treatment of multiple sclerosis: a pilot study. J Neurol Neurosurg Psychiatry 1993;56:1217-1218.
19. Goodkin DE, Rudick RA, Medendorp SV, et al. Low-dose (7.5mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995;37:30-40.
20. Goodkin DE, Rudick RA, Medendorp SV, Daughtry MM, Van Dyke C.I. Low-dose oral methotrexate in chronic progressive multiple sclerosis: analysis of serial MRIs. Neurology 1996;47:1153-57.
21. Romine JS, Sipe JC, Koziol JA, Beutler E. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Physicians 1999;111:35-44.
22. Rice GPA, for the Cladribine Clinical Study Group; and Filippi M, Comi G, for the Cladribine MRI Study Group. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Neurology 2000;54:1145-1155.
23. Rudge P, Koester JC, Mertin J, et al. Randomized double blind controlled trial of cyclosporin in multiple sclerosis. J Neurol Neurosurg Psychiatry 1989;52:559-565.
24. The Multiple Sclerosis Study Group. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded placebo-controlled trial. Ann Neurol 1990;27:591-605.
25. Kappos L, Patzold U, Dommasch D, et al. Cyclosporine versus azathioprine in the long-term treatment of multiple sclerosis: results of the german multicenter study. Ann Neurol 1988;23:56-63.
26. Stewart DJ, Green RM, Mikhael NZ, Montpetit V, Thibault M, Maroun JA. Human autopsy tissue concentrations of mitoxantrone. Cancer Treat Rep 1986;70:1225-1261.
27. Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997;62:112-118.
28. Millefiorini E, Gasperini C, Pozzilli C, et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis:24-month clinical and MRI outcome. J Neurol 1997;244:153-159.
29. Hartung HP, Gonsette R, and the MIMS Study Group. Mitoxantrone in progressive multiple sclerosis. A placebo-controlled, randomized, observer-blind European phase III Multicenter study. Clinical Results. Multiple Sclerosis 1998;4:325.
30. Weinshenker BG. Therapeutic plasma exchange in multiple sclerosis. In Rudick R, Goodkin D. Multiple sclerosis therapeutics. London: Martin Dunitz Ltd, 1999:323-333.
31. Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999;46:878-86.
32. Marmont AM. Immune ablation followed by allogenic or autologous bone marow transplantation: a new treatment for severe autoimmune disease? Stem Cell 1994;12:125-135.
33. Fassas A, Anagnostopoulos A, Kasis A, et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant 1997;20:631-638.
34. Comi G, Kappos L, Clanet M, et al. Guidelines for autologous blood and marrrow stem transplantation in multiple sclerosis: a consensus report written on behalf of the European Group for Blood and Marrow Transplantation and the European Charcot Foundation. BMT-MS Study Group. J Neurol 2000;247:376-382.
35. Weiner HL. A 21 point unifying hipothesis on the etiology and treatment of multiple sclerosis. Can J Neurol Sci 1998;25:93-101.
36. Patti F, Cataldi ML, Nicoletti F, Reggio E, Nicoletti A, Reggio A. Combination of cyclophosphamide and interferon-beta halts progression in patients in with rapidly transitional multiple sclerosis. J Neuro Neurosurg Psychiatry 2001;71:404-7.
37. Lublin FD, Reingold SC. Combination therapy for treatment of multiple sclerosis. Ann Neurol 1998;44:7-9.
38. Rieckmann P, Toyka KV. Escalating immunotherapy of multiple sclerosis. Austrian- German- Swiss Multiple Sclerosis Therapy Consensus Group [MSTCG] Eur Neurol 1999;42:121-127.